ALSYMPCA trial: Ra-223 effective and well-tolerated for CRPC with symptomatic bone metastases

Bookmark and Share
Published: 1 Feb 2014
Views: 3921
Rating:
Save
Dr Sten Nilsson - Karolinska University Hospital, Stockholm, Sweden

Dr Sten Nilsson from Karolinska University Hospital, Stockholm, Sweden joins ecancer at ASCO GU 2014 to discuss recent data from the phase III ALSYMPCA trial. The discussion includes how radium-223 is an effective treatment against mCRPC and bone metastases.